The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of Ͼ0.5 ؋ 10 9 /l and a platelet count of Ͼ20 ؋ 10 9 /l were 9 and 11 days. Severe neutropenia (Ͻ0.1 ؋ 10 9 /l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Grampositive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.
antibacterial agents now available, life-threatening infections continue to occur in myelosuppressed patients. [1] [2] [3] [4] [5] A growing body of data indicates that infusion of stem cells harvested from peripheral blood (PBSC) may lead to more rapid hematopoietic recovery after high-dose therapy when compared with bone marrow infusion. [6] [7] [8] [9] The administration of granulocyte colony-stimulating factor (G-CSF) after PBSC autografting further accelerates the rate of neutrophil engraftment. 10, 11 This more rapid hematopoietic recovery (median time to neutrophil count Ͼ0.5 ϫ 10 9 /l and the period of severe neutropenia are reduced to 9-10 and 4-6 days, respectively) 12,13 may decrease the incidence and seriousness of infectious complications associated with high-dose therapy. In addition, antimicrobial prophylactic regimens have been found to be effective in the prevention of infections in patients undergoing autologous bone marrow transplantation. [14] [15] [16] [17] [18] In this report we present the results of an extensive prophylactic antimicrobial regimen with ciprofloxacin, itraconazole, and acyclovir after high-dose chemotherapy and autologous PBSC. We prospectively analyzed the spectrum, timing, and complications of infectious episodes and subsequent empiric management of neutropenic fever with imipenem as initial antibiotic monotherapy.
Patients and methods
Between April 1992 and July 1996, 126 patients of less than 60 years of age with solid tumors or lymphomas fulfilled eligibility criteria for high-dose chemotherapy and were consecutively included in the autologous PBSC protocol of our institution. All patients signed an informed consent to participate in the study as approved by the Institutional Review Board.
One or two weeks prior to PBSC procurement, all patients underwent restaging and were assessed by physical examination, a complete blood count and standard blood chemistry, serological tests, urine culture, ECG, echocardiography with calculation of the ejection fraction, and appropriate studies to determine the extent of malignancy. To be included in the study, patients were required to have a Karnofsky performance status of 70 or greater, creatinine clearance of 55 ml/min or greater, aspartate aminotransferase, alanine aminotransferase and total bilirubin level of less than three times the upper limit of normal, and cardiac ejection fraction of 55% or greater. Patients with CNS metastases or bone marrow involvement with tumor were excluded. The characteristics of patients are shown in Table  1 . Mobilization regimens consisted of 10 g/kg/day of recombinant human G-CSF (rhG-CSF, filgrastim) given alone (n = 78) or after chemotherapy (n = 48) until a total of at least 2 ϫ 10 6 CD34 + cells/kg patient weight had been harvested by leukapheresis. Prior to mobilization, a doublelumen subclavian catheter was placed in all patients. No active infection was present in any patient at the time of initiation of high-dose therapy.
The high-dose chemotherapy regimen used in 104 patients with breast and ovarian cancer consisted of cyclophosphamide ( + cells/kg). All but 10 patients received rhG-CSF post-infusion at a daily dose of 5 g/kg/day from day 0 (n = 65) or from day +5 (n = 51). Supportive care during myelosuppression included private rooms equipped with positive-pressure ventilation systems and high-efficiency particulate air filters, bacteriacontrolled diet, reverse isolation precautions, and transfusion of packed red blood cells when the hemoglobin level was less than 9 g/dl or platelets when the platelet count was below 15 ϫ 10 9 /l. Toxicities were graded using the common toxicity criteria of the World Health Organization. 22 A febrile episode was defined as a temperature above 38°C for 30 min or more, or a single temperature above 38.4°C. In the event of fever, patients were evaluated by physical examination and cultures from urine and suspected sites. Blood cultures were obtained through the two lumens of the catheter and a peripheral vein. This protocol was repeated daily if fever persisted and each time when there was a new febrile episode. Blood cultures were performed in an automated system (BacT/Alert; Organon Teknika, Durham, NC, USA). Infection was defined as the presence of signs and/or symptoms of inflammation at anatomic sites. Infections were classified as microbiologically documented when pathogenic microorganisms were recovered from affected sites and clinically documented when pathogenic microorganisms were not recovered. Standard definitions of bacteremia, sepsis and catheter-related infections were used. [23] [24] [25] At least two positive blood cultures were required to diagnose a coagulasenegative Staphylococcus bacteremia. Unexplained febrile episodes were defined as fever without a localizing source of infection or recovery of pathogenic organisms. A breakthrough bacteremia was defined as any bacteremia which occurred while the patient was receiving empiric, broadspectrum antibiotics.
Febrile patients were initially treated with empiric i.v. imipenem (500 mg every 6 h). Vancomycin, 1 g every 12 h (0.5 g through each lumen of the catheter) was added if fever persisted for 48-72 h. Amikacin (7.5 mg/kg every 12 h) was given to supplement this regimen if fever persisted for 5 days, and amphotericin B lipid complex (5 mg/kg/day) was further given on day 7 or 8 of febrile neutropenia. All antibiotics were discontinued after the patient had been afebrile for 5 days or at the time of neutrophil recovery (granulocyte count Ͼ0.5 ϫ 10 9 /l) unless the patient had a documented infection. In these cases, antibiotic therapy was continued for a variable period of time on the basis of clinical judgement. In patients with microbiologic evidence of gram-negative bacteria, amikacin was added, and in those with evidence of gram-positive bacteria, vancomycin was added. Prophylactic itraconazole was substituted for fluconazole (100 mg every 12 h) in patients with evidence of mucosal candidiasis.
Patients were hospitalized from the day before high-dose chemotherapy was initiated until hematological recovery or until discharge from the hospital in good clinical condition after treatment of any infectious or noninfectious complication. Duration of hospital stay was defined as the length of time between PBSC infusion and hospital discharge.
Statistical analysis
Infections and complications occurring during the transplant period (from day Ϫ8 to day +30) were analyzed. Data obtained in patients with unexplained fever and in patients with documented infection as being either clinically or microbiologically evident were compared by means of the 2 test and the Mann-Whitney and Wilcoxon tests. Shortterm hematopoietic recovery was assessed by the KaplanMeier method. The Kaplan-Meier curves were compared with the log-rank test.
Results
After autologous PBSC transplantation, the median time to achieve a neutrophil count Ͼ0.5 ϫ 10 9 /l was 9 days (range 7-30 days). The median time with a neutrophil count Ͻ0.5 ϫ 10 9 /l was 8 days (range 6-30 days). Severe neutropenia defined as a neutrophil count Ͻ0.1 ϫ 10 9 /l lasted for a median period of 5 days (range 4-27 days). The median number of days to attain a platelet count Ͼ20 ϫ 10 9 /l was 11 (range 7-42 days). Duration of hospital stay ranged from 9 to 64 days (median 13 days). Median red cell and platelet transfusions were 2 (range 0-8) and 3 (range 1-29), respectively. Six patients (5%) required parenteral nutrition and there was one toxic death due to acute respiratory distress syndrome (ARDS).
Febrile episodes
Of the total 126 patients, 69 (55%) had unexplained fever and 50 (40%) had clinically or microbiologically documented infection. The median day of fever onset was day +4 (range Ϫ8 to +13). The frequency histogram of fever onset is shown in Figure 1 . During the initial nonneutropenic period (from day Ϫ8 to day 0) there was a low incidence of febrile episodes (n = 13); the majority were documented infections (9/13, 69%) and mostly due to catheter infection (7/9, 78%). The median number of days with fever was 2 (range 0-16) and with neutropenic fever 2 (range 0-7). Median days on antibiotic therapy and number of antibiotics used were 7 (range 0-30) and 2 (0-6), respectively.
Imipenem was administered to 116 (92%) patients for a median number of 5 days (range 1-22), vancomycin to 68 (54%) for a median of 5 days (range 1-29), amikacin to 20 (16%) patients for a median of 5 days (range 1-15), and erythromycin to 7 (6%) for a median of 7 days (range 4-11). Amphotericin B was given to three (2%) patients, in one as empiric antibiotic therapy and in two for treating lung aspergillosis. Patients with clinically or microbiologically documented infection required significantly more supportive measures and showed a greater number of days to attain a platelet count Ͼ20 ϫ 10 9 /l than did those with unexplained fever (Table 2) .
Bacteremia
Forty episodes of bacteremia were diagnosed in 39 (31%) patients. The frequency histogram of bacteremia onset is shown in Figure 2 . Gram-positive bacteria were isolated in 30 episodes of bacteremia, 25 of which were caused by coagulase-negative staphylococci (catheter-related infections in 24). One patient had a polymicrobial catheterrelated infection due to Staphylococcus aureus and Staphylococcus epidermidis which was the single case of break-through bacteremia in these series (1%). Methicillinresistant strains were isolated in 18 cases and methicillinsensitive in eight. Other gram-positive bacteria were Streptococcus viridans in three cases and Corynebacterium spp in one. Gram-negative pathogens were isolated in 10 episodes of bacteremia. In seven patients, bacteremia due to gram-negative pathogens was related to infection of the catheter. Characteristics of patients with bacteremia are shown in Table 3 .
Catheter-related infections
Infections related to the intravascular central line were documented in 35 (28%) patients. Catheter-associated bacteremia was diagnosed in 33 of them (Table 3 ). The remaining two patients had infections at the catheter insertion site caused by Staphylococcus epidermidis in one case and by S. epidermidis and Corynebacterium spp in the other which were treated without removal of the catheter.
Pulmonary infection
Eleven (9%) patients had an infection of the lower respiratory tract. In nine patients with cough, dyspnea, and persistent fever or fever recrudescence, typical features of consolidation were observed on the chest X-ray film. No bacterial or fungal pathogen was isolated (brochoalveolar lavage was performed in five patients) except in two patients who had catheter-associated bacteremia caused by S. epidermidis and A. denitrificans concurrently. In all nine patients, pulmonary infection resolved with empiric broadspectrum antibiotic therapy with the exception of one patient who developed an ARDS and nonimmunologic platelet refractoriness, and died due to cerebral hemorrhage.
The remaining two patients developed peripheral nodular pulmonary infiltrates and had a negative microbiological screen on bronchoalveolar lavage. Computed tomography scans of the chest showed several small peripheral nodules with straight edges and surrounding low attenuation (the halo sign) that were highly suggestive of invasive aspergill- osis. They both responded successfully to amphotericin B followed by itraconazole.
Other infections
Other infections included candidiasis in eight patients (oropharyngeal in five, genital in three) that resolved with fluconazole, severe oral gingivitis in three, herpetic infections in three (herpes simplex type 1 in two, herpes zoster in one), cellulitis in two patients (one developed S. epidermidis bacteremia), and anal abscess in one. In addition, enteric infections were diagnosed in three patients: one patient with neutropenic enterocolitis and engraftment delay with concomitant catheter-related bacteremia caused by S. aureus and S. epidermidis; another patient with clinical symptoms of enteritis complicated by bacteremia due to Fusobacterium spp; and the remaining patient who was readmitted to hospital because of clinical manifestations of gastroenteritis associated with high fever, and successfully treated with ceftazidime and ornidazole for 6 days. With regard to extrahematologic toxicity, macroscopic hemorrhagic cystitis occurred in three patients. Grade 3 nausea and vomiting was found in 50 patients and grade 4 in four, grade 3 mucositis in 29 patients and grade 4 in three, grade 3 liver dysfunction in 11 patients and grade 4 in 10, grade 3 diarrhea in seven patients, and hemorrhagic complications in four patients. All complications were successfully managed. There were no cases of hepatic venoocclusive disease.
Discussion
This study shows that autologous PBSC transplantation combined with the administration of rhG-CSF, and antimicrobial prophylaxis with ciprofloxacin, itraconazole, and acyclovir did not prevent the occurrence of febrile episodes in the majority of patients (94%) undergoing high-dose chemotherapy and the need of treatment with broadspectrum antibiotics. In our series, mainly comprising solid tumors treated with standard chemotherapy a decrease in the incidence of bacteremia (31%) was not observed in comparison to an historical series of autologous bone marrow transplants with or without G-CSF. 4, 5, [26] [27] [28] [29] In 75% of cases, bacteremia was due to gram-positive microorganisms, especially coagulase-negative staphylococci (62%) in association with catheter-related infections. This may be due in part to the use of quinolones prophylactically. 16, 17, 30 Since the majority of patients undergoing high-dose chemotherapy with autologous bone marrow transplant develop fever from the second to the fourth day of severe neutropenia, 31 the persistence of a 5-day period of severe neutropenia in our series may have contributed to the lack of success in attempting to decrease the incidence of febrile episodes and bacteremias. Seventy-two percent of febrile episodes occurred during the 5 days of severe neutropenia (from day +2 to day +6), which also coincides with the maximal incidence of bacteremia (50%).
On the other hand, rapid hematologic recovery led to the rapid resolution of both unexplained fever and clinically or microbiologically documented infections, with a median duration of fever of only 2 days. This permitted a significant reduction in antibiotic use, ie a median of two antibiotics given intravenously, a median of 7 days on antibiotic therapy, and only 2% of patients treated with amphotericin B, which is in contrast to a median of four to seven antibiotics, 11-23 days on antibiotic therapy, and 30-80% of patients given amphotericin B in the series of autologous bone marrow transplants with or without G-CSF. 4, 5, [26] [27] [28] [29] 32 Patients with clinically or microbiologically documented infection required more supportive measures with a higher requirement for antibiotics and blood products. They also experienced a longer period to platelet recovery, possibly due to platelet overdestruction associated with sepsis and antimicrobial therapy. 33 Autologous PBSC transplantation, particularly when G-CSF is administered after infusion, [10] [11] [12] [13] 34 has been followed by a clear tendency to decrease duration of febrile episodes, consumption of antibiotics, and also length of hospital stay. Another important factor is the number of CD34 + cells infused. Eighty percent of patients in this study received Ͼ5 ϫ 10 6
CD34
+ cells/kg which has been correlated with more rapid hematological recovery than when fewer are infused. 35, 36 This prompt hematologic recovery may also be responsible for the minimal incidence of break-through bacteremia (1%).
The risk of developing invasive fungal infections increases particularly after 2 weeks of neutropenia, 2, 18 and the risk of superficial fungal infections after 10 days. 18 A 2% incidence of invasive aspergillosis was observed, similar to that reported in the series of autologous bone marrow transplants, 37 despite a shorter period of neutropenia and the use of filters and prophylactic itraconazole. A number of studies have indicated that the administration of itraconazole could prevent infections caused by Aspergillus in neutropenic patients but its gastrointestinal absorption is erratic, [38] [39] [40] especially in patients treated with high-dose chemotherapy. 41, 42 The eight (6%) patients with mucosal candidiasis were cured by fluconazole, 200 mg/day. The use of imipenem as initial antibiotic monotherapy, supplemented with vancomycin or amikacin according to persistence of fever and clinical or microbiologic documentation of the febrile episodes, resulted in good control of the infections associated with autologous PBSC transplantation and, without doubt contributed to the low antibiotic requirement in our series. Although monotherapy with carbapenems in febrile neutropenic patients is currently accepted, [43] [44] [45] we believe that its introduction in high-dose chemotherapy programs should be restricted to hospital settings with a low incidence of gram-negative infections and low incidence of virulent gram-positive flora.
Catheter-associated infections should be treated with appropriate antibiotics. Removal of the catheter, however, is usually required under certain circumstances, such as subcutaneous cellulitis extending over 2 cm around the insertion point, catheter-related bacteremia caused by gramnegative microorganisms, S. aureus, Candida, Myocobacteria, Bacillus, or in the presence of deterioration of the patient's clinical condition, recurrent infection or blood cultures persistently positive. 24, 25, 46, 47 In this study, 73% of catheter-related infections were caused by coagulasenegative staphylococci and successfully treated without removal of the intravascular line.
Despite reduction in the number of neutropenic days allowed by autologous PBSC transplantation, the majority of patients treated with high-dose chemotherapy developed fever, and 40% of them clinically or microbiologically documented infections. Therefore, it is important to introduce new strategies to decrease toxicity and associated infections in order to facilitate treatment of these patients on an outpatient basis and to reduce health care costs. Gilbert et al 48 have recently reported a promising experience with the prophylactic use of rifampicin and ciprofloxacin because only 57% of patients had fever, 13% documented infections, and none bacteremia. On the other hand, ex vivo expansion techniques of hematopoietic progenitor cells 49 and/or the development of new cytokines have been advocated to reduce the days of absolute neutropenia.
